Description
Genetic Technology is one of the closest-watched areas in healthcare and in the past two years Kalorama Information has published major studies on different aspects of this market. This Kalorama Information Bundle consists of four major reports in biotech equipment:
- DNA Sequencing Equipment Markets: Markets, Forecasts, Sequencer Product Reviews and Company Profiles
- SNP Genotyping Markets: Single base pair mutations that occur at a specific site in the DNA sequence, the most common type of genetic variation between human beings. Because they are responsible for over 80% of the variation between two individuals, SNPs are ideal for the task of hunting for correlations between genotype and behavior or quality exhibited by a living organism.
- Gene Expression Profiling Markets (Coverage of Gene Expression in Biomarkers, Pharmacogenetics / Pharmacogenomics, Infectious Disease Research, Cancer Diagnostics and Prognostics, and Diagnosis and Prognosis of Other Diseases
- Analytical Chip/BioChip Markets (Includes Lab on a Chip, DNA/Gene, Protein, and other Microarrays)
These reports, the result of Kalorama’s biotech analyst Justin Saek’s and Kenneth Krul’s investigation into the biotech markets.
Table of Contents
Gene Expression
CHAPTER ONE: EXECUTIVE SUMMARY
- Background and Definitions
- Alternative Splicing; Splice Variant Microarrays
- Cap Analysis of Gene Expression (CAGE)
- Comparative Genomic Hybridization (CGH)
- Methylation, Other Epigenetic Analysis
- Serial Analysis of Gene Expression (SAGE)
- Tissue Arrays / Microarrays
- Transcript Analysis with Affinity Capture (TRAC)
CHAPTER TWO: APPLICATIONS
- Pharmacogenetics / Pharmacogenomics
- Cancer Diagnosis, Prognosis, Sub-Classification
- Infectious Disease Research
- Diagnostic / Prognostic Technologies and Applications
CHAPTER THREE: INDUSTRY, TECHNOLOGY, AND REGULATORY TRENDS
- Gene Expression Profiling Becoming Established Tool
- Various Types of Small RNA Gaining Importance
- Gene Expression Analysis Moves Gradually into Diagnostics
- Quality Control of RNA Samples Becoming Standard Process
- New Technologies Entering Gene Expression Analysis Market
- Questions Remain Regarding Housekeeping and Reference Genes
- Probe Length Still Varying Greatly Between Vendors
- Amplification Remains Key Aspect of Experiments
- Sample Preparation Becoming High Priority
- March 2004 – Critical Path Initiative
- March 2005 – “Guidance for Industry – Pharmacogenomic Data Submissions”
- April 2005 – “Drug-Diagnostic Co-Development Concept Paper”
- March 2006 – Critical Path Opportunities List
- November 2006 – “Recommendations for the Generation and Submission of Genomic Data”
- August 2007 – “Pharmacogenomic Data Submissions — Companion Guidance”
CHAPTER FOUR: PRODUCTS AND SERVICES FOR RESEARCH APPLICATIONS
- TaqMan Gene Expression Assays
- Ambion (an Applied Biosystems Business)
- GenomeLab GeXP Genetic Analysis System
- GenomeLab GeXP Rat MultitoxPlex Panel
- BioOdyssey Calligrapher MiniArrayer
- Experion Automated Electrophoresis System
- Experion Automated Electrophoresis System
- Experion Priming Station, Experion Vortex Station
- CAL Fluor Dyes, Quasar Dyes, Black Hole Quencher Dyes
- Epicentre Biotechnologies
- ArrayPure Nano-scale RNA Purification Kit
- MessageBOOSTER cDNA Synthesis Kit for qPCR
- TargetAmp aRNA Amplification Kits
- DASL Assay Focused Arrays Genome-Wide Expression BeadChips
- Multiplex Transcription Factor Assays
- QuantiGene 2.0 Reagent System
- SideStep and SideStep II Products and Kits
- Next-Generation Sequencers
- Diagnostic, Prognostic, Theranostic Products
- BiblioSphere Pathway Edition
CHAPTER FIVE: CONSORTIA, INITIATIVES, STANDARDIZATION, DEALS
- External RNA Controls Consortium (ERCC)
- MicroArray Quality Control (MAQC) Project
- Minimum Information About a Microarray Experiment (MIAME)
- NIH Roadmap for Medical Research
- Institutional Clinical and Translational Science Awards (CTSA’s) Program (October 2005)
- Toxicogenomics Research Consortium
- Other Experiments to Assess Comparability, Reproducibility
CHAPTER SIX: MARKET ANALYSIS
- Affymetrix as Bellwether for Microarray Segment
- Applied Biosystems as Bellwether for qRT-PCR Segment
- Estimated 2006 Gene Expression Revenues
- Estimated 2006 Gene Expression Revenues
- Estimated 2006 Life Sciences and Chemical Analysis Group Revenues
- Estimated 2006 Gene Expression Revenues
- Estimated 2006 Gene Expression Revenues
- Estimated 2006 Gene Expression Revenues
CHAPTER SEVEN: CHALLENGES & STRATEGIC RECOMMENDATIONS
- Next-Generation Sequencers Create Wild Card
- Affymetrix Dominance Decreasing But Still Significant
- Market Complicated by New Gene Expression & Regulation Analysis Products
- Pharmaceutical Industry Tightening Budgets, Scrutinizing Technologies
- Regulations for Diagnostics Still Shaking Out
- RT-PCR Competing Strongly with Microarrays
- SNP Analysis and Copy Number Variation Easier and Popular
- Growth Threatened by Industrialization, Commoditization
- Resistance Towards Diagnostics Using Multiple Markers
- Data Analysis and Management Still Hindering End-Users
- Multiplexing Limitations of Real Time Quantitative PCR
- Longer-Term Prospects Threatened by Proteomics, Metabolomics
- Strategic Recommendations
- Diversify Into Multiple Aspects, Applications
- Partner With Market Leaders
- Provide Software Tools for Comparison Across Platforms, Techniques
- Investigate Intellectual Property and Licensing Possibilities
LIST OF EXHIBITS
CHAPTER TWO: APPLICATIONS
- Table 2-1: Areas Using Gene Expression Profiles in Infectious Disease Research
CHAPTER THREE: INDUSTRY, TECHNOLOGY, AND REGULATORY TRENDS
- Table 3-1: Critical Path Opportunities List (March 2006)
CHAPTER FOUR: PRODUCTS AND SERVICES FOR RESEARCH APPLICATIONS
- Table 4-1: Selected Gene Expression Analysis Products
- Table 4-2: Selected List of Next-Generation Sequencer Products and Technologies
- Table 4-3: Selected List of Next-Generation Sequencer Products and Technologies
- Table 4-4: Selected List of Software Products Available for the Gene Expression Analysis Market
CHAPTER FIVE: CONSORTIA, INITIATIVES, STANDARDIZATION, DEALS
- Table 5-1: Selected Deals Taking Place in the Gene Expression Analysis Market
CHAPTER SIX: MARKET ANALYSIS
- Figure 6-1: Revenues for Microarrays, Instruments, and Reagents (2001- 2007)
- Figure 6-2: Revenues for Microarrays, Instruments, and Reagents with Trendlines (2004- 2007)
- Figure 6-3: Revenues for Real-Time PCR/Applied Genomics (2001-2007)
- Table 6-1: Forcasted Revenues in the Gene Expression Market (2006-2012)
- Figure 6-4: Forecasted Revenues in the Gene Expression Analysis Market (2006-2012)
- Table 6-2: Growth Rates Forecast (2006-2012)
- Figure 6-5: Growth Rates Forecast Chart (2006-2012)
- Table 6-3: Gene Expression Product Revenues Regional Breakdown and Trend 2006
- Figure 6-6: Gene Expression Product Revenues Regional Market Share 2006
- Table 6-4: Regional Shares of Affymetrix’s Overall Revenues (2001-2006)
- Figure 6-7: Trending in the Regional Share of Affymetrix’s Overall Revenues (2001-2006)
- Table 6-5: Estimated Revenues and Market Shares for the Top Vendors in the Gene Expression Analysis
- Figure 6-8: Estimated Market Shares for the Top Vendors in the Gene Expression Analysis Chart
- CHAPTER ONE: EXECUTIVE SUMMARY
- CHAPTER TWO: INTRODUCTION
- Allele discrimination / assay reaction mechanism
- Single Nucleotide Addition; Pyrosequencing
- Single-Nucleotide Polymorphism (SNP)
- CHAPTER THREE: APPLICATIONS
- Pharmacogenetics / Pharmacogenomics
- Case Study #1 — SNPs in Gene for P-glycoprotein Affect Antidepressant Response
- Case Study #2 – Celera Studying SNPs Associated With Heart Disease
- Case Study #3 – Synonymous SNPs Alter mRNA Splicing with Obesity
- Case Study #4 – University of Ottawa Heart Institute (UOHI) Coronary Artery
- CHAPTER FOUR: INDUSTRY AND REGULATORY TRENDS
- Consolidation Occurring in Array and Life Science Markets
- FDA Involvement Making Drug Industry More Comfortable
- Acceptance of SNP Analysis, Pharmacogenetics Reached Tipping Point
- Core Labs Becoming Established Paradigm
- Increased Multiplexing Expands Applications
- End-Users Attracted to Larger-Scale SNP Platforms
- Complexity of Biological Systems Requires Multiple Techniques
- Miniaturization of Equipment and Instruments
- March 2005 – “Guidance for Industry – Pharmacogenomic Data Submissions”
- April 2005 – “Drug-Diagnostic Co-Development Concept Paper”
- March 2006 – Critical Path Opportunities List
- November 2006 – “Recommendations for the Generation and Submission of
- August 2007 – “Pharmacogenomic Data Submissions — Companion Guidance”
- August 2007 – FDA Updates Labeling of Warfarin (Coumadin)
- December 2007 – EGAPP Reviews Use of CYP450 Genetic Testing For SSRIs
- Overview of Affymetrix Products
- Overview of Applied Biosystems Products
- LI-COR Biosciences (Lincoln, NE)
- Polymorphic DNA Technologies
- CHAPTER SIX: CONSORTIA, GOVERNMENT INVOLVEMENT, DEALS
- Consortia, Collaborative Projects
- The Cancer Genome Atlas (TCGA) Pilot Project
- Cancer Sequencing Project
- DNA Polymorphism Discovery Resource
- Genetic Association Information Network (GAIN)
- Genotype-To-Phenotype Database (GEN2PHEN)
- International HapMap Project
- Introduction & Background
- Rationale for HapMap Approach
- Process for Producing HapMap
- Populations Included in HapMap
- Measures Taken to Protect Donors’ Privacy
- Laboratories and Technologies Involved in HapMap
- Practical Use of the HapMap Data
- MicroArray Quality Control (MAQC) Project
- NIH Roadmap for Medical Research
- Pharmacogenetics Research Network (PGRN)
- NIH Involvement, Funding for SNPs and Sequencing
- Funding for Sequencing Projects Affecting SNP Market
- Continued Rapid Growth in Sequence Production
- Funding and Consortia for Sequencing
- NHGRI Funds Large-Scale Sequencing Centers, 2006
- CHAPTER SEVEN: MARKET DATA AND COMPETITIVE ANALYSIS
- Illumina as Bellwether for SNP Analysis Market
- Applied Biosystems as Bellwether for RT-PCR Products
- CHAPTER EIGHT: CORPORATE PROFILES
- CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
- Cheaper Sequencing Creates Competition for SNP Analysis Platforms
- Market Is Dominated by a Small Number of Suppliers
- Issues Arise With Use of Public Databases
- Data Management Requirements Limit Large-Scale Technologies
- Diagnostic Market Holds Obstacles For New Innovations
- Backlash Against Rush Into Genetic Testing, DTC Marketing
- Standard Processes for SNP Experiments Still Not Established
- Shortcomings in Sample Preparation and Handling Hinder Success
- Privacy Concerns Pose Threat to Broad Technology Adoption
- Strategic Recommendations
- CHAPTER ONE: EXECUTIVE SUMMARY
- Figure-1-1: SNP Analysis Market 2007-2013
- Figure 1-2: Growth Rate in SNP Analysis Revenues 2008-2013
- CHAPTER TWO: INTRODUCTION
- Table 2-1 Adelle-Specific Invasive Cleavage
- Table 2-2 Adelle-Specific Ligation
- Table 2-1 Allele-Specific Primer Extension
- Table 2-4 Single Base Primer Extension
- CHAPTER FOUR: INDUSTRY AND REGULATORY TRENDS
- Table 4-1: Critical Path Opportunities List
- Figure 5-1: Taq Man Assay
- Figure 5-2: SOLID System Average Throughput Progress
- Figure 5-3: SNPstream Method
- Figure 5-4: Roche SimpleProbe System
- Figure 5-5: Roche HybProbe System
- Table 5-1 Products in the SNP Analysis Market
- Table 5-2 Public SNP Tools and Resources (Tool, Website)
- CHAPTER SIX: CONSORTIA, GOVERNMENT INVOLVEMENT, DEALS
- Figure 6-1: Domains of Genomes Sequenced by Year (Archaea, Bacteria, Eukaryota)
- Major Sequencing Centers, Jan 2008
- Figure 6-5: Top Funding Agencies, DNA Sequencing, 2008
- Figure 6-4: Major Sequencing Centers and Percent of Sequencing Projects (WORLD, GENOSCOPE, BMC, Sanger, WashU, BROAD, JCVI, JGI), Jan 2008
- Figure 6-5: Top Funding Agencies, DNA Sequencing, 2008 ($M)
- Figure 6-6: Human Genome Project Funding, DOE& NIH ’90-‘03
- Figure 6-7: Areas Funding Genome Sequencing, Jan 2008 (Medical, Evolutionary, Agricultural, Environmental, Biotechnology)
- Table 6-5: Large-Scale Sequencing Centers, NHGRI Funding, 2004-2006
- Figure 6-8: Top Genome Sequencing Countries, Jan. 2008 (# projects)
- Figure 6-9: SNP Analysis Related Deals (Companies, Date, Details of Deal)
- Figure 6-10: SNP: NHGRI Funded Large-Scale Sequencing Ctrs, ‘07
- Table 6-6: SNP Analysis-Related Deals (Companies, Date, Details of Deal)
- CHAPTER SEVEN: MARKET DATA AND COMPETITIVE ANALYSIS
- Figure 7-1: Illumina Quarterly Revenues, 2001-2007 ($M)
- Figure 7-2: Applied Biosystems Revenues in Real Time PCR/Applied Genomics
- Table-7-1: Forecasted Revenues in the SNP Analysis Market
- Figure-7-3: Forecasted Revenues in the SNP Analysis Market
- Table 7-2: Growth Rate in SNP Analysis Tools Market, 2008-2013
- Figure 7-4: Growth Rate in SNP Analysis Tools Market, 2008-2013
- Figure 7-5: SNP Analysis Revenues by Region (North America, Europe, Rest of World)
- Table 7-3: SNP Analysis Revenues by Region (North America, Europe, Rest of World)
- Figure 7-6 SNP Market by Product Segment (Instruments, Consumables, Software & Services)
- Table 7-4: SNP Market by Segment (Instruments, Consumables, Software & Services)
- Table 7-5: Revenues Among the Top Companies in SNP Analysis (Illumina, Affymetrix, Applied Biosystems, Other)
- Figure 7-7: SNP Analysis Market Share, 2007
- CHAPTER EIGHT: CORPORATE PROFILES
- Figure 8-1: Affymetrix’ Revenues by Product Type, 2004 – 2007
- Figure 8-2: Illumina BeadStation Installed Base, 2004-2006
- CHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONS
- Figure 9-1: Estimated Decrease in Screening Price
- CHAPTER ONE: Executive Summary
- DNA Sequencing Applications
- CHAPTER TWO: Introduction
- DNA Sequencing Applications
- DNA Sequencing Strategies
- DNA Sequencing Chemistries and Techniques
- Single Nucleotide Addition; Pyrosequencing
- Cyclic Reversible Terminators
CHAPTER THREE: Sequencer Market Trends and
- Market Fragmenting Into Multiple Applications, Products
- Synergies Appearing Between Companies’ Products
- Microbes and Metagenomics Gaining Importance
- Various Disruptive Technologies Rapidly Appearing On Market
- Miniaturization of Sanger and CE Technology
- Paired-End Techniques, Increasing Read-Lengths Expanding Applications
- Development of Multiplexing Approaches Extends Market
- SNP and Other Experiments Moving to Sequencing for Higher Detail
- Continued Rapid Growth in Sequence Production
- Funding and Consortia for Sequencing
- The Cancer Genome Atlas Pilot Project
- Cancer Sequencing Project
- FUGE – Functional Genomics in Norway
- NSF / USDA Microbial Genome Sequencing Program
CHAPTER FOUR: DNA Sequencer Products
- 454 Life Sciences (Branford, CT) / Roche
- Applied Biosystems (Foster City, CA)
- ABI Prism 310 Genetic Analyzer
- ABI Prism 3100-Avant Genetic Analyzer
- Applied Biosystems 3100 Genetic Analyzer
- Applied Biosystems 3130 Genetic Analyzer
- Applied Biosystems 3130xl Genetic Analyzer
- Applied Biosystems 3730 DNA Analyzer
- Applied Biosystems 3730xl DNA Analyzer
- LI-COR Biosciences (Lincoln, NE)
CHAPTER FIVE: Market Data
CHAPTER SIX: Competitive Analysis
- Features and Strengths of Next-Generation Sequencers
- 454 Life Sciences – Strengths / Advantages
- 454 Life Sciences – Weaknesses / Disadvantages
- Applied Biosystems SOLiD – Strength / Advantages
- Applied Biosystems SOLiD – Weaknesses / Disadvantages
- Illumina Genome Analyzer – Strength / Advantages
- Illumina Genome Analyzer – Weaknesses / Disadvantages
CHAPTER SEVEN: Intellectual Property and Litigation
- Affymetrix Wins Patent Infringement Case Against Illumina
- Applied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent Litigation
- Applied Biosystems Sues Solexa and Former Chief Patent Counsel
- Beckman Coulter and Applied Biosystems Settle Outstanding Legal Disputes
- Cepheid and Idaho Technology Settle Dispute Over PCR Patents
- Enzo Biochem Disputes CalTech Sequencing Patents
CHAPTER EIGHT: Deals
CHAPTER NINE: Corporate Profiles
- 454 Life Sciences (Branford, CT) / Roche
- Applied Biosystems (Foster City, CA)
- Beckman Coulter (Fullerton, CA)
- GE Healthcare Life Sciences (Little Chalfont, UK)
- Helicos Biosciences (Cambridge, MA)
- Intelligent Bio-Systems (Waltham, MA)
- LI-COR Biosciences (Lincoln, NE)
CHAPTER TEN: Technologies Under Development
- NHGRI Funds Next Generation of Sequencing Technologies
- “Massively Parallel High Throughput, Low Cost Sequencing”
- “454 Life Sciences Massively Parallel System DNA Sequencing”
- Agencourt Personal Genomics [Applied Biosystems]
- “Bead-based Polony Sequencing”
- Arizona State University, Tempe
- “Multiplexed Reactive Sequencing of DNA”
- Baylor College of Medicine, Human Genome Sequencing Ctr
- “Ultrafast SBS Method for Large-Scale Human Resequencing”
- “An Integrated System for DNA Sequencing by Synthesis”
- Harvard University, Rowland Institute; moved to Boston Univ.
- “Ultra-fast Nanopore Readout Platform for Designed DNA’s”
- “Single-Molecule DNA Sequencing Using Charge-Switch dNTPs”
- Microchip Biotechnologies Inc
- “Microbead INtegrated DNA Sequencer (MINDS) System”
- “High-Throughput, Single-Molecule DNA Sequencing”
- Stanford Genome Technology Center
- “Pyrosequencing Array for DNA Sequencing”
- University of Gainesville, Florida
- “DNA Sequencing Using Nanopores”
- “Polymerases for Sequencing by Synthesis”
- Second Group of Grants, $1000 Genome
- Arizona State University, Tempe
- “Molecular Reading Head for Single-Molecule DNA Sequencing”
- Oak Ridge National Laboratory
- “Experimental R&D for Rapid Sequencing Nanotechnology”
- “Computational R&D for Rapid Sequencing Nanotechnology”
- “Single Molecule Nucleic Acid Detection with Nanopipettes”
- University of British Columbia, Vancouver
- “Nanopores for Trans-Membrane Bio-Molecule Detection”
- University of Maine, Orono
- “High-speed Nanopore Gene Sequencing”
- University of North Carolina, Chapel Hill
- “Nanotechnology for the Structural Interrogation of DNA”
- NHGRI Expands Effort to Revolutionize Sequencing Technologies
- Agencourt Personal Genomics [Applied Biosystems]
- “Bead-Based Polony Sequencing (Supplemental)”
- “$100,000 Genome Using Integrated Microfluidic CE”
- The State University of New York, Stony Brook (SUNY)
- “Ultra High Throughput DNA Sequencing System Based on 2D Monolith
- Multi-Capillary Arrays and Nanoliter Reaction Volume”
- “Modulating Nucleotide Size in DNA for Detection by Nanopore”
- “Droplet-Based Digital Microfluidic Genome Sequencing”
- “Electronic Sequencing in Nanopores”
- “Real-Time Multiplex Single-Molecule DNA Sequencing”
- “Haplotype Sequencing Via Single Molecule Hybridization”
- Oxford University and The Scripps Research Institute
- “Single-Molecule DNA Sequencing with Engineered Nanopores”
- University of California, San Diego
- “Massively Parallel Cloning and Sequencing of DNA”
- University of Illinois at Urbana-Champaign
- “Sequencing a DNA Molecule Using a Synthetic Nanopore”
- “Real-Time DNA Sequencing”
- “NHGRI Aims to Make DNA Sequencing Faster, More Cost Effective”,
- “Fabrication of Universal DNA Nanoarrays for Sequencing by Hybridization”
- “High-Throughput DNA Sequencing Using Design Polymers and Nanopore Arrays”
- Case Western Reserve University
- “Large-Scale Nanopore Arrays for DNA Sequencing”
- General Electric Global Research
- “Closed Complex Single Molecule Sequencing”
- “High Accuracy Single Molecule DNA Sequencing by Synthesis”
- “Force Spectroscopy Platform for Label Free Genome Sequencing”
- University of California, San Diego
- “Genome Sequencing by Ligation Using Nano-Arrays of Single DNA Molecules”
- University of North Carolina, Chapel Hill
- “Nanoscale Fluidic Technologies for Rapidly Sequencing Single DNA Molecules”
- University of Washington, Seattle
- “Engineering MspA for Nanopore Sequencing”
- Baylor College of Medicine, HGS
- “Ultrafast SBS Method for Large-Scale Human Resequencing”
- “High-Throughput DNA Sequencing by Synthesis Platform”
- Other Microfluidics and Lab-on-a-Chip
CHAPTER ELEVEN: Challenges and Strategic
- Saturation, Technology Advances Threaten Market Growth
- Next-Generation Vendors Contending With 454’s Head-Start
- Rapid Changes, Multiple Variables Creating Unpredictable Market
- Labs Hesitant to Invest in Unproven Technologies
- Segments Resisting Change Where Long Read-Lengths Key
- New Technologies Create Data Management Issues
- Recent Acquisitions Make Tougher Environment for New Entrants
- Strategic Recommendations
- Increase Products’ Value Through Software Tools
- Explore Demand in Expanding Industry Segments
- Address Niche Markets Resulting From Fragmentation
- Increase Value by Combining with Complementary Content
- Establish Early Connections With End-Users
- Balance Risks by Diversifying Applications
- Move Towards Diagnostic Environment Requires Partnering
table of exhibits
CHAPTER ONE: Executive Summary
- Table 1-1: DNA Sequencer Equipment Revenues 1999-2006
- Figure 1-1: Trending in the DNA Sequencer Equipment Market 2006-2012
Chapter three: Sequencer Market Trends and Funding Trensd
- Figure 3-1: Distribution of Archaeal and Bacterial Genome Projects, Q1 2007
- (JGI, TIGR, J Venter, World)
- Figure 3-2: Phylogenetic Distribution of Bacterial Genome Projects, Q1 ’07
- Figure 3-3: Number of Completely Sequenced Genomes (Published vs
- Unpublished) 1999 through Q1 2007
- Figure 3-4: Distribution of Number of Projects Among Major Sequencing Centers Q1 2007
- Figure 3-5: Funding by the Top Agencies in DNA Sequencing
- Figure 3-6: U.S. Funding for the Human Genome Project DOE vs NIH 1990-2003
- Figure 3-7: Distribution of the Number of Bacterial Sequencing Projects by Area of Focus (Agriculture/Food, Biomedical, Biotech, Environmental, Evolutionary)
- Table 3-1: FUGE Funding Recipients
- Table 3-2 Large-Scale Sequencing Centers NHGRI Funding, 2007
- Figure 3-8: NHGRI Funding of Large-Scale Sequencing Centers by Organization 2004-2006 (cumulative)
- Figure 3-9: NHGRI Funding of Large-Scale Sequencing Centers by Organization 2007 Figure 3-10: Broad Institute Organizational Structure
- Table 3-3: NSF Plant Genome Research Project Recent Funding Awards (Title Start Date, Expiration Date, PI, Organizatino, Funding Amount) Table 3-4: NSF / USDA Microbial Genome Sequencing Program Recent
- Funding Awards (Title, Start Date, Expiration Date, PI, Organization, Funding Amount)
Chapter four: DNA Sequencer Products
- Table 4-1: Key Products and Technologies Currently on the Market by Company (Company, Product/ Technology, Comments)
Chapter five: Market Data
- Table 5-1: DNA Sequencer Equipment Revenues 1999-2006
- Table 5-2: DNA Sequencer Equipment Revenues 2006-2012
- Figure 5-1 DNA Sequencer Market, Market Share by Industry, 2006
- Figure 5-2: Trending in the DNA Sequencer Equipment Market 1999-2006
- Figure 5-3: ABI’s Quarterly Overall Sequencing Revenues 2001 to 2006
- Figure 5-4: ABI’s Quarterly Overall Sequencing Revenues Q3 2005 to Q4 2006
- Figure 5-5: Estimated Forecasted Price of Sequencing a Genome 1990-2030
- Figure 5-6: Trending in the DNA Sequencer Equipment Market, 2006-2012
Chapter SIX: Competitive Analysis
- Table 6-1: Revenues and Market Shares of Leading DNA Sequencer System
- Suppliers, 2006 (Company, Market Share, Revenues, Trend)
- Figure 6-1: Market Shares, DNA Sequencer Systems, 2006
- Table 6-2: Comparison of Next-Generation Sequencer System Features (Reads,
- Read Length, Number of Samples at Once, BP Output, Cost Comparison with Sanger/ CE, Consumable Cost per Run)
chapter seven: Intellectual Property and Litigation
- Table 7-1: Selected Sequencing-Related Patents Assigned or Licensed to Applied
- Biosystems (Assignee, Title, Patent #)
Chapter eight: Deals
- Table 8-1: Notable Deals in Recent Years (Companies, Date, Details
Chapter ten: Technologies Under Development
- Table 10-1: First Set of NHGRI “$100,000 Genome” Grant Awardees
- October 2004 (Awardee, Title, Amount, Term)
- Table 10-2: First Set of NHGRI “$1,000 Genome” Grant Awardees
- October 2004 (Awardee, Title, Amount, Term)
- Table 10-3: Second Set of NHGRI “$100,000 Genome” Grant Awardees
- August 2005 (Awardee, Title, Amount, Term)
- Table 10-4: Second Set of NHGRI “$1,000 Genome” Grant Awardees
- August 2005 (Awardee, Title, Amount, Term)
- Table 10-5: Latest Set of NHGRI “$1,000 Genome” Grant Awardees
- October 2006 (Awardee, Title, Amount, Term)
- Table 10-6: Latest Set of NHGRI “$100,000 Genome” Grant Awardees
- October 2006 (Awardee, Title, Amount, Term)
- Table 10-7: Selected Group s Workingon Microfluidics for DNA Sequencing
- Applications (Number of Channels, Read Length, Time)
CHAPTER ONE: Executive Summary
- Size and Growth of Market
- Analytical Microchips Market
- Analytical Chips for DNA/Gene Microarrays
- Analytical Chips for Protein Microarrays
- Analytical Chips for Microbiology Microarrays
- Analytical Chips for Tissue Microarrays
- Analytical Chips for Cell Microarrays
- Analytical Process Microchips
- Key Occurances in the Analytical Chip Market
CHAPTER TWO: Introduction
- Early Analytical Chip Products
CHAPTER THREE: DNA/Gene Biochips
- DNA/Gene Microarray Production
- DNA/Gene Microarray Applications
- Gene Expression Measurement
- DNA/Gene Microarray Informatics
- Microbiology Array Technology
- Microbiology Microarray Applications
- Drug/Vaccine Discovery and Development
- Microbiology Microarray Commercialization
CHAPTER FOUR: Protein Microarrays
- Protein Array Applications
- Drug Discovery and Development
- Protein Microarray Commercialization
CHAPTER FIVE: Cell and Tissue Microarray
- Cell Microarray Technology
- Cell Microarray Applications
- Transcriptional Regulation
- Drug Discovery and Development
- Cell Microarray Commercialization
- Tissue Microarray Technology
- Tissue Microarray Commercialization
- CHAPTER SIX: Process Microchips: Lab-On-A-Chip Technology
CHAPTER SEVEN: Company Profiles
- Accelr8 Technology Corporation
- Agilent Technologies, Inc.
- TeleChem International, Inc.
CHAPTER EIGHT: Market Analysis
CHAPTER NINE: Conclusions and Strategic Implications
APPENDIX
table of exhibits
Executive Summary
Figure 1-1: The Market Potential for Analytical Microchips in the United States: 2007 – 2017
Table 1-1 : Estimated Market Potential for United States Market for Analytic Microchips: 2007 – 2017 by Application (DNA/Gene, Protein, Cell, Tissue, Microbiology, Process)
Figure 1-2 : Growth in the United States Market Potential for DNA/Gene Microarray Products: 2007 – 2017
Figure 1-3 : Growth in the United States Market for Protein Microarray Products: 2007 – 2017
Figure 1-4 : Growth in the United States Market for Microbiological Microarray Products: 2007 – 2017
Figure 1-5: Growth in the United States Market for Tissue Microarray Products: 2007 – 2017
Figure 1-6 : Growth in the United States Market for Cell Microarray Products: 2007 – 2017
Figure 1-7 : Growth in the United States Market for Process Microchip Products: 2007 – 2017
ChAPTER THREE: DNA/Gene and Microbiology Microarrays
- Table 3-1:Selected Genomics Databases
CHAPTER FOUR: Protein Microarrays
- Table 4-1: Key Competitors in Antibody and Protein Microarray Technology
- Cell and Tissue Microarray
CHAPTER FIVE: Cell and Tissue Microarray
- Table 5-1: Key Competitors in Cell and Tissue Microarray Technology
- Process Microchips: Lab-On-A-Chip Technology
CHAPTER SIX: Process Microchips: Lab-On-A-Chip Technology
- Table 6-1: Advantages and Disadvantages of LOC Technology
- Table 6-2: Key Competitors in Cell Process Microchip (LOC) Technology
CHAPTER EIGHT: Market Analysis
- Table 8-1: Historic and Projected United States Market Potential for Analytical Microarrays: 2007-2017
- Table 8-2 Historic and Projected United States Market Potential for DNA/Gene Microarrays: 2007-2017
- Figure 8-2 Trends in the Historic and Projected United States Market Potential for DNA/Gene Microarrays: 2007-2017
- Table 8-3 Historic and Projected United States Market Potential for Protein Microarrays: 2007-2017
- Figure 8-3: Trends in the Historic and Projected United States Market Potential for Protein Microarrays: 2007-2017
- Table 8-4: Historic and Projected United States Market Potential for Cell Microarrays: 2007-2017
- Figure 8-4: Trends in the Historic and Projected United States Market Potential for Cell Microarrays: 2007-2017
- Table 8-5: Historic and Projected United States Market Potential for Tissue Microarrays: 2007-2017
- Figure 8-5 Trends in the Historic and Projected United States Market Potential for Tissue Microarrays: 2007-2017
- Table 8-6: Historic and Projected United States Market Potential for Microbiology Microarrays: 2007-2017
- Figure 8-6: Trends in the Historic and Projected United States Market Potential for Microbiology Microarrays: 2007-2017
- Table 8-7: Historic and Projected United States Market Potential for Process Microchips: 2007-2017
- Figure 8-7: Trends in the Historic and Projected United States Market Potential for Process Microchips: 2007-2017 229
